Oculis (NASDAQ:OCS) Shares Gap Up – Should You Buy?

Shares of Oculis Holding AG (NASDAQ:OCS) gapped up before the market opened on Monday . The stock had previously closed at $11.31, but opened at $11.95. Oculis shares last traded at $11.9810, with a volume of 65,189 shares traded.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Wall Street Zen cut Oculis from a “sell” rating to a “strong sell” rating in a research note on Sunday, July 12th. Stifel Nicolaus decreased their price objective on shares of Oculis from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, June 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a report on Friday, July 17th. Guggenheim decreased their price objective on Oculis from $75.00 to $45.00 and set a “buy” rating for the company in a report on Monday, June 1st. Finally, Robert W. Baird lowered their price target on Oculis from $49.00 to $38.00 and set an “outperform” rating on the stock in a report on Monday, June 1st. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Oculis presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.33.

Oculis Stock Up 0.8%

The company has a quick ratio of 5.18, a current ratio of 5.18 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $695.18 million, a PE ratio of -5.63 and a beta of 0.51. The firm’s fifty day moving average is $13.07 and its 200-day moving average is $22.55.

Oculis (NASDAQ:OCS) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). The business had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.25 million. Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. On average, equities research analysts predict that Oculis Holding AG will post -2.27 earnings per share for the current year.

Hedge Funds Weigh In On Oculis

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Gildi lifeyrissjodur purchased a new stake in Oculis during the fourth quarter worth about $50,250,000. Perceptive Advisors LLC purchased a new position in Oculis in the 4th quarter valued at approximately $9,862,000. SR One Capital Management LP raised its holdings in Oculis by 98.8% during the fourth quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock worth $12,801,000 after purchasing an additional 318,522 shares during the last quarter. Alyeska Investment Group L.P. boosted its position in Oculis by 152.3% during the fourth quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock worth $6,617,000 after purchasing an additional 200,000 shares in the last quarter. Finally, Folketrygdfondet purchased a new stake in Oculis during the fourth quarter worth $3,651,000. 22.30% of the stock is owned by institutional investors and hedge funds.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.